To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05147493
Title A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hellenic Society of Hematology
Indications
Therapies
Age Groups: senior | adult
Covered Countries GRC

Facility Status City State Zip Country Details
General Hospital of Athens "Evangelismos" Athens 106 76 Greece Details
Anticancer Oncology Hospital of Athens "Agios Savvas" Athens 115 22 Greece Details
General Hospital of Athens "Alexandra" Athens 115 28 Greece Details
University General Hospital of Ioannina Ioannina 455 00 Greece Details
University General Hospital of Patra Patra 265 04 Greece Details
Anticancer Hospital of Thessaloniki "Theageneio" Thessaloniki 546 39 Greece Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field